1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Building Partnerships and Broadening Perspectives to Advance Ethical, Legal, and Social Implications (ELSI) Research (BBAER) Program (UM1), Clinical Trial Optional is sponsored by National Human Genome Research Institute (NHGRI). This limited competition NOFO supports transdisciplinary ELSI research addressing timely, complex, and understudied topics associated with advances in human genetics and genomics.
It specifically aims to establish ELSI research teams that include partnerships with relevant communities affected by and with an interest in the proposed research, research capacity building, and workforce development opportunities for early career scholars and research team members.
Eligible applicants are domestic organizations located in the United States and its territories that received less than $30 million per year in total NIH funding for the past three fiscal years, and are underrepresented among those receiving NHGRI funding for ELSI research.
Get alerted about grants like this
Get emailed when new opportunities from “National Human Genome Research Institute (NHGRI)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Domestic organizations located in the United States and its territories that received less than $30 million per year in total NIH funding for the past three fiscal years. Confirm the full requirements in the official notice before applying.
The published deadline was July 31, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Building Partnerships and Broadening Perspectives to Advance Ethical, Legal, and Social Implications (ELSI) Research (BBAER) Program (UM1), Clinical Trial Optional is funded by National Human Genome Research Institute (NHGRI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
While headlines chase AI and defense money, USDA's National Institute of Food and Agriculture runs a tight summer competitive cycle — Equipment Grants (June 25), Agricultural Genome to Phenome (June 29), New Beginning for Tribal Students (July 2), and Crop Protection and Pest Management (July 6). Here is how the four programs fit together, who is eligible, and why the land-grant system has a structural edge.
Read articleThe STOMP program funds measurement tools and removal therapies for microplastics in human tissue. Proposals due June 22. Eligibility, phases, and strategy.
Read articleThe Complement-ARIE program funds seven technology centers to develop human-based models that complement animal research. What it means for drug developers, academic researchers, and the regulatory pipeline.
Read article